Professor Raphael Mechoulam Joins ABcann's Research and Advisory Board To Support Development of Standardized Medical Cannabis for Clinical Trials

NAPANEE, ON / ACCESSWIRE / May 14, 2015 / ABcann Medicinals Inc., a licensed producer under the new Marihuana for Medical Purposes Regulations (MMPR), is pleased to announce that Professor Raphael Mechoulam has joined the ABcann Research and Advisory Board. Professor Mechoulam's involvement on the board will play an integral role in helping to shape ABcann's research initiatives and programs with regards to developing standardized medical cannabis for clinical trials.

Professor Raphael Mechoulam, often regarded as the "Father of Marijuana Research", is an Israeli Organic Chemist and professor from the Department for Medicinal Chemistry and Natural Products at the Hebrew University of Jerusalem. Professor Mechoulam's history with cannabis began in 1963 when he determined the structure of cannabidiol (CBD) and by 1964 isolated and synthesized tetrahydrocannabinol (THC). One of his most noteworthy achievements was in 1992 when he isolated and elucidated the structure of the brain's first endogenous cannabinoid, Anandamide. Professor Mechoulam has since become essential in the advancement of cannabis research in relation to the brain with regards to memory, appetite and pain.

An excerpt of a recent letter from Professor Mechoulam states, "...in pediatric epilepsy CBD should be the main, or the only, cannabinoid administered. For lowering the side effects of cancer chemotherapy THC should be the main component" when describing the different ratios of cannabis compounds. He continues, "A patient should know - and be sure - that he/she is getting the same material throughout his treatment. A physician has to know exactly what his patient is being administered - as with all drugs prescribed" when discussing ABcann's standardization efforts.

ABcann has currently committed to over $2 million dollars in research initiatives with leading institutions which includes the development of controlled environmental growth chambers. These chambers are capable of controlling every aspect of the growth process, producing a repeatable and consistent product. Professor Mechoulam's involvement with ABcann will assist in identifying research opportunities to develop drug standards generally accepted by the physicians and patients.

Professor Raphael Mechoulam is currently scheduled to deliver a lecture to the professional medical community in June 2015. This lecture will be hosted by Queens University - School of Medicine and sponsored by ABcann Medicinals. For more information about the event, please email at info@abcann.ca or call at 1-855-322-2266.

ABOUT ABCANN MEDICINALS INC.

ABcann Medicinals Inc. is an approved Licensed Producer (cultivation only) under the Marihuana for Medical Purposes Regulations (MMPR). We believe that every patient deserves access to truly standardized medical cannabis! Throughout our company and with each process built, our focus remains on creating an organic product that is safe, repeatable and reliable, time after time, because...we care.

SOURCE: ABcann Medicinals Inc.